Skip to main content
Erschienen in: Supportive Care in Cancer 6/2014

01.06.2014 | Original Article

Functional benefits are sustained after a program of supervised resistance exercise in cancer patients with bone metastases: longitudinal results of a pilot study

verfasst von: Prue Cormie, Daniel A. Galvão, Nigel Spry, David Joseph, Dennis R. Taaffe, Robert U. Newton

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Exercise may represent an effective adjunct therapy to current medical management strategies for maintaining functional independence and improving quality of life in cancer patients with bone metastatic disease. However, it has yet to be determined if there are any sustained effects following the completion of an exercise program by patients with bone metastases.

Purpose

The aim of this study is to determine whether a 3-month supervised resistance exercise program results in any sustained functional benefits in prostate and breast cancer patients with bone metastatic disease.

Methods

Twenty men and women with bone metastatic disease secondary to prostate or breast cancer completed a 3-month supervised resistance exercise program followed by a 6-month observation period. Outcomes were assessed at baseline, post-exercise, and 6-month follow-up.

Results

Fourteen participants completed the follow-up observation period. Significant improvements in physical function (4–6 %), physical activity levels (~160 min/week), lean mass (3–4 %), and quality of life (5–7 %) were observed at the completion of the exercise program. At the 6-month follow-up, significant improvements in ambulation (4 %), physical activity level (~105 min/week), whole body lean mass (2 %), and quality of life (13 %) remained.

Conclusions

An appropriately designed and supervised 3-month resistance exercise program may lead to significant improvements in functional ability, physical activity level, lean mass, and quality of life that remain 6 months after completion of the program in cancer patients with bone metastases. Future trials involving larger sample sizes are required to expand these preliminary findings.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Abellan van Kan G (2009) Epidemiology and consequences of sarcopenia. J Nutr Health Aging 13:708–712PubMedCrossRef Abellan van Kan G (2009) Epidemiology and consequences of sarcopenia. J Nutr Health Aging 13:708–712PubMedCrossRef
2.
Zurück zum Zitat Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM (2012) Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 104:815–840PubMedCentralPubMedCrossRef Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM (2012) Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 104:815–840PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Bjorner JB, Wallenstein GV, Martin MC, Lin P, Blaisdell-Gross B, Tak Piech C, Mody SH (2007) Interpreting score differences in the SF-36 vitality scale: using clinical conditions and functional outcomes to define the minimally important difference. Curr Med Res Opin 23:731–739PubMedCrossRef Bjorner JB, Wallenstein GV, Martin MC, Lin P, Blaisdell-Gross B, Tak Piech C, Mody SH (2007) Interpreting score differences in the SF-36 vitality scale: using clinical conditions and functional outcomes to define the minimally important difference. Curr Med Res Opin 23:731–739PubMedCrossRef
4.
Zurück zum Zitat Borg G (1998) Borg's perceived exertion and pain scales. Human Kinetics, Champaign Borg G (1998) Borg's perceived exertion and pain scales. Human Kinetics, Champaign
5.
Zurück zum Zitat Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology, and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRef Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology, and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRef
6.
Zurück zum Zitat Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clezardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ (2010) Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 36:615–620PubMedCentralPubMedCrossRef Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clezardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ (2010) Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 36:615–620PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvao DA (2013) Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases Prostate Cancer and Prostatic Disease Aug 6 [Epub ahead of print] Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvao DA (2013) Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases Prostate Cancer and Prostatic Disease Aug 6 [Epub ahead of print]
8.
Zurück zum Zitat Courneya KS, Friedenreich CM (2011) Physical activity and cancer. In: physical activity and cancer. Springer, City, p 387CrossRef Courneya KS, Friedenreich CM (2011) Physical activity and cancer. In: physical activity and cancer. Springer, City, p 387CrossRef
9.
Zurück zum Zitat Edwards MH, Jameson K, Denison H, Harvey NC, Sayer AA, Dennison EM, Cooper C (2013) Clinical risk factors, bone density, and fall history in the prediction of incident fracture among men and women. Bone 52:541–547PubMedCentralPubMedCrossRef Edwards MH, Jameson K, Denison H, Harvey NC, Sayer AA, Dennison EM, Cooper C (2013) Clinical risk factors, bone density, and fall history in the prediction of incident fracture among men and women. Bone 52:541–547PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Ferriolli E, Skipworth RJ, Hendry P, Scott A, Stensteth J, Dahele M, Wall L, Greig C, Fallon M, Strasser F, Preston T, Fearon KC (2012) Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy? J Pain Symptom Manage 25 Jan [Epub ahead of print] Ferriolli E, Skipworth RJ, Hendry P, Scott A, Stensteth J, Dahele M, Wall L, Greig C, Fallon M, Strasser F, Preston T, Fearon KC (2012) Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy? J Pain Symptom Manage 25 Jan [Epub ahead of print]
11.
Zurück zum Zitat Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU (2006) Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 38:2045–2052PubMedCrossRef Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU (2006) Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 38:2045–2052PubMedCrossRef
12.
Zurück zum Zitat Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R (2008) Changes in muscle, fat, and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 102:44–47PubMedCrossRef Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R (2008) Changes in muscle, fat, and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 102:44–47PubMedCrossRef
13.
Zurück zum Zitat Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2009) Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure. Prostate Cancer Prostatic Dis 12:233–240PubMedCrossRef Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2009) Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure. Prostate Cancer Prostatic Dis 12:233–240PubMedCrossRef
14.
Zurück zum Zitat Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28:340–347PubMedCrossRef Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28:340–347PubMedCrossRef
15.
Zurück zum Zitat Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE (2012) Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 9, CD007146PubMed Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE (2012) Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 9, CD007146PubMed
16.
Zurück zum Zitat Hechmati G, Cure S, Gouepo A, Hoefeler H, Lorusso V, Luftner D, Duran I, Garzon-Rodriguez C, Ashcroft J, Wei R, Ghelani P, Bahl A (2013) Cost of skeletal-related events in European patients with solid tumors and bone metastases: data from a prospective multinational observational study. J Med Econ 16:691–700PubMedCrossRef Hechmati G, Cure S, Gouepo A, Hoefeler H, Lorusso V, Luftner D, Duran I, Garzon-Rodriguez C, Ashcroft J, Wei R, Ghelani P, Bahl A (2013) Cost of skeletal-related events in European patients with solid tumors and bone metastases: data from a prospective multinational observational study. J Med Econ 16:691–700PubMedCrossRef
17.
Zurück zum Zitat Higano CS (2008) Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 5:24–34PubMedCrossRef Higano CS (2008) Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 5:24–34PubMedCrossRef
18.
Zurück zum Zitat Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA (2005) Physical activity and survival after breast cancer diagnosis. JAMA 293:2479–2486PubMedCrossRef Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA (2005) Physical activity and survival after breast cancer diagnosis. JAMA 293:2479–2486PubMedCrossRef
20.
Zurück zum Zitat Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Gilliland FD, Ballard-Barbash R (2005) Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23:774–782PubMedCentralPubMedCrossRef Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Gilliland FD, Ballard-Barbash R (2005) Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23:774–782PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Jacobs DR Jr, Ainsworth BE, Hartman TJ, Leon AS (1993) A simultaneous evaluation of ten commonly used physical activity questionnaires. Med Sci Sports Exerc 25:81–91PubMedCrossRef Jacobs DR Jr, Ainsworth BE, Hartman TJ, Leon AS (1993) A simultaneous evaluation of ten commonly used physical activity questionnaires. Med Sci Sports Exerc 25:81–91PubMedCrossRef
22.
Zurück zum Zitat Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM (2011) Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 29:726–732PubMedCentralPubMedCrossRef Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM (2011) Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 29:726–732PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Li EC, Davis LE (2003) Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 25:2669–2708PubMedCrossRef Li EC, Davis LE (2003) Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 25:2669–2708PubMedCrossRef
25.
Zurück zum Zitat Lipton A (2003) Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 8:469–488PubMedCrossRef Lipton A (2003) Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 8:469–488PubMedCrossRef
26.
Zurück zum Zitat Loriot Y, Massard C, Fizazi K (2012) Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. Ann Oncol 23:1085–1094PubMedCrossRef Loriot Y, Massard C, Fizazi K (2012) Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. Ann Oncol 23:1085–1094PubMedCrossRef
27.
Zurück zum Zitat Lynch ME, Brooks D, Mohanan S, Lee MJ, Polamraju P, Dent K, Bonassar L, van der Meulen MCH, Fischbach C (2013) In vivotibial compression decreases osteolysis and tumor formation in a human metastatic breast cancer model. J Bone Miner Res 28:2357–2367PubMedCrossRef Lynch ME, Brooks D, Mohanan S, Lee MJ, Polamraju P, Dent K, Bonassar L, van der Meulen MCH, Fischbach C (2013) In vivotibial compression decreases osteolysis and tumor formation in a human metastatic breast cancer model. J Bone Miner Res 28:2357–2367PubMedCrossRef
28.
Zurück zum Zitat Myers AM, Fletcher PC, Myers AH, Sherk W (1998) Discriminative and evaluative properties of the activities-specific balance confidence (ABC) scale. J Gerontol A Biol Sci Med Sci 53:M287–M294PubMedCrossRef Myers AM, Fletcher PC, Myers AH, Sherk W (1998) Discriminative and evaluative properties of the activities-specific balance confidence (ABC) scale. J Gerontol A Biol Sci Med Sci 53:M287–M294PubMedCrossRef
29.
Zurück zum Zitat National Cancer Institute (2009) Common Terminology Criteria for Adverse Events (CTCAE). U.S. Department of Health and Human Services, National Institute of Health, City, pp. 196 National Cancer Institute (2009) Common Terminology Criteria for Adverse Events (CTCAE). U.S. Department of Health and Human Services, National Institute of Health, City, pp. 196
30.
Zurück zum Zitat Popovic M, Nguyen J, Chen E, Di Giovanni J, Zeng L, Chow E (2012) Comparison of the EORTC QLQ-BM22 and the FACT-BP for assessment of quality of life in cancer patients with bone metastases. Expert Rev Pharmacoecon Outcomes Res 12:213–219PubMedCrossRef Popovic M, Nguyen J, Chen E, Di Giovanni J, Zeng L, Chow E (2012) Comparison of the EORTC QLQ-BM22 and the FACT-BP for assessment of quality of life in cancer patients with bone metastases. Expert Rev Pharmacoecon Outcomes Res 12:213–219PubMedCrossRef
31.
Zurück zum Zitat Price DD, McGrath PA, Rafii A, Buckingham B (1983) The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 17:45–56PubMedCrossRef Price DD, McGrath PA, Rafii A, Buckingham B (1983) The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 17:45–56PubMedCrossRef
32.
Zurück zum Zitat Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, Bandera EV, Hamilton KK, Grant B, McCullough M, Byers T, Gansler T (2012) Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 62:242–274CrossRef Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, Bandera EV, Hamilton KK, Grant B, McCullough M, Byers T, Gansler T (2012) Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 62:242–274CrossRef
34.
Zurück zum Zitat Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860–1867PubMedCrossRef Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860–1867PubMedCrossRef
35.
Zurück zum Zitat Saad F, Olsson C, Schulman CC (2004) Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol 46:731–739, discussion 739-740PubMedCrossRef Saad F, Olsson C, Schulman CC (2004) Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol 46:731–739, discussion 739-740PubMedCrossRef
36.
Zurück zum Zitat Sayer AA, Syddall HE, Martin HJ, Dennison EM, Anderson FH, Cooper C (2006) Falls, sarcopenia, and growth in early life: findings from the Hertfordshire cohort study. Am J Epidemiol 164:665–671PubMedCentralPubMedCrossRef Sayer AA, Syddall HE, Martin HJ, Dennison EM, Anderson FH, Cooper C (2006) Falls, sarcopenia, and growth in early life: findings from the Hertfordshire cohort study. Am J Epidemiol 164:665–671PubMedCentralPubMedCrossRef
37.
Zurück zum Zitat Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K (2013) New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 63:309–320PubMedCentralPubMedCrossRef Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K (2013) New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 63:309–320PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL (2010) American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42:1409–1426PubMedCrossRef Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL (2010) American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42:1409–1426PubMedCrossRef
39.
Zurück zum Zitat Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo ME, Wells GA (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21:1653–1659PubMedCrossRef Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo ME, Wells GA (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21:1653–1659PubMedCrossRef
40.
Zurück zum Zitat Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud'Homme DG, Malone SC, Wells GA, Scott CG, Slovinec D'Angelo ME (2009) Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 27:344–351PubMedCrossRef Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud'Homme DG, Malone SC, Wells GA, Scott CG, Slovinec D'Angelo ME (2009) Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 27:344–351PubMedCrossRef
41.
Zurück zum Zitat Stein KD, Jacobsen PB, Blanchard CM, Thors C (2004) Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage 27:14–23PubMedCentralPubMedCrossRef Stein KD, Jacobsen PB, Blanchard CM, Thors C (2004) Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage 27:14–23PubMedCentralPubMedCrossRef
42.
Zurück zum Zitat von Haehling S, Morley JE, Anker SD (2010) An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachex Sarcopenia Muscle 1:129–133CrossRef von Haehling S, Morley JE, Anker SD (2010) An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachex Sarcopenia Muscle 1:129–133CrossRef
43.
Zurück zum Zitat Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRef Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRef
44.
Zurück zum Zitat Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579–584PubMedCrossRef Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579–584PubMedCrossRef
45.
Zurück zum Zitat Wickham C, Cooper C, Margetts BM, Barker DJ (1989) Muscle strength, activity, housing, and the risk of falls in elderly people. Age Aging 18:47–51CrossRef Wickham C, Cooper C, Margetts BM, Barker DJ (1989) Muscle strength, activity, housing, and the risk of falls in elderly people. Age Aging 18:47–51CrossRef
46.
Zurück zum Zitat Yu HH, Tsai YY, Hoffe SE (2012) Overview of diagnosis and management of metastatic disease to bone. Cancer Control 19:84–91PubMed Yu HH, Tsai YY, Hoffe SE (2012) Overview of diagnosis and management of metastatic disease to bone. Cancer Control 19:84–91PubMed
47.
Zurück zum Zitat Zabora J, BrintzenhofeSzoc K, Jacobsen P, Curbow B, Piantadosi S, Hooker C, Owens A, Derogatis L (2001) A new psychosocial screening instrument for use with cancer patients. Psychosomatics 42:241–246PubMedCrossRef Zabora J, BrintzenhofeSzoc K, Jacobsen P, Curbow B, Piantadosi S, Hooker C, Owens A, Derogatis L (2001) A new psychosocial screening instrument for use with cancer patients. Psychosomatics 42:241–246PubMedCrossRef
Metadaten
Titel
Functional benefits are sustained after a program of supervised resistance exercise in cancer patients with bone metastases: longitudinal results of a pilot study
verfasst von
Prue Cormie
Daniel A. Galvão
Nigel Spry
David Joseph
Dennis R. Taaffe
Robert U. Newton
Publikationsdatum
01.06.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 6/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-2103-1

Weitere Artikel der Ausgabe 6/2014

Supportive Care in Cancer 6/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.